Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring.

Bergenstal RM, Strock E, Mazze R, Powers MA, Monk AM, Richter S, Souhami E, Ahrén B

Diabetes/metabolism research and reviews28 Feb 2017Cited by 6 (Europe PMC)

PMID28032465DOI10.1002/dmrr.2879PepBankPUB-28032465

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes receiving prebreakfast lixisenatide, total daily glucose exposure decreased from baseline to study end.
In plain wordsDaily blood sugar exposure decreased from baseline in patients receiving lixisenatide before breakfast.
Peptide
Lixisenatide
Outcome
Decrease24-hour total glucose exposure, before-breakfast group
Study
n = 40
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Total glucose exposure
4198.1 mg/dL*24 h
breakfast group, baseline
SD
652.3 mg/dL*24 h
breakfast group, baseline
Total glucose exposure
3681.2 mg/dL*24 h
breakfast group, study end
SD
699.6 mg/dL*24 h
breakfast group, study end
P value
< 0.0001
breakfast group
Source sentences
Summary
Between baseline and end of study, mean (standard deviation) total glucose exposure decreased from 4198.1 (652.3) to 3681.2 (699.6) mg/dL*24 h in the breakfast group (P < .0001)
2 context sentences(design, population, supporting numbers)
Summary · context
In the parent study of this analysis, patients with type 2 diabetes received lixisenatide before breakfast or the main meal of the day.
Summary · context
A subset of patients from the parent study underwent 2 14-day periods of continuous glucose monitoring (CGM) at the start and end of the 24-week study.
Report a problemFND-2803246501
02HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes receiving prebreakfast lixisenatide, HbA1c decreased by approximately 0.6% from baseline.
In plain wordsLong-term blood sugar decreased from baseline in patients receiving lixisenatide before breakfast.
Peptide
Lixisenatide
Outcome
DecreaseHbA1c change, before-breakfast group
Study
n = 40
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
HbA1c decrease
≈ 0.6%
breakfast group
Source sentences
Summary
For patients included in the substudy, HbA_1c decreased by approximately 0.6% in both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Data were available for 69 patients in the substudy, 40 from the original breakfast group and 29 from the main meal group.
Summary · context
In the parent study of this analysis, patients with type 2 diabetes received lixisenatide before breakfast or the main meal of the day.
Summary · context
A subset of patients from the parent study underwent 2 14-day periods of continuous glucose monitoring (CGM) at the start and end of the 24-week study.
Report a problemFND-2803246503
03HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes receiving prebreakfast lixisenatide, glucose exposure after the standardized meal decreased significantly from baseline.
In plain wordsBlood sugar exposure after a standardized meal decreased from baseline in patients receiving lixisenatide before breakfast.
Peptide
Lixisenatide
Outcome
Decrease4-hour total glucose exposure after standardized meal
Study
n = 40
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Total glucose exposure decrease
168.9 mg/dL*4 h
breakfast group
SD
158.4 mg/dL*4 h
breakfast group
P value
< 0.0001
change from baseline
Source sentences
Summary
Mean (standard deviation) 4-hour total glucose exposure fell by 168.9 (158.4) mg/dL*4 h (P < .0001) from baseline.
3 context sentences(design, population, supporting numbers)
Summary · context
The breakfast group consumed a standardized meal during both CGM periods to determine change in 4-hour glycemic response.
Summary · context
In the parent study of this analysis, patients with type 2 diabetes received lixisenatide before breakfast or the main meal of the day.
Summary · context
A subset of patients from the parent study underwent 2 14-day periods of continuous glucose monitoring (CGM) at the start and end of the 24-week study.
Report a problemFND-2803246505
04HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes receiving pre-main-meal lixisenatide, total daily glucose exposure decreased from baseline to study end.
In plain wordsDaily blood sugar exposure decreased from baseline in patients receiving lixisenatide before their main meal.
Peptide
Lixisenatide
Outcome
Decrease24-hour total glucose exposure, before-main-meal group
Study
n = 29
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Total glucose exposure
4127.9 mg/dL*24 h
main meal group, baseline
SD
876.8 mg/dL*24 h
main meal group, baseline
Total glucose exposure
3880.9 mg/dL*24 h
main meal group, study end
SD
1165 mg/dL*24 h
main meal group, study end
P value
0.0224
main meal group
Source sentences
Summary
and from 4127.9 (876.8) to 3880.9 (1165.0) mg/dL*24 h in the main meal group (P = .0224).
2 context sentences(design, population, supporting numbers)
Summary · context
In the parent study of this analysis, patients with type 2 diabetes received lixisenatide before breakfast or the main meal of the day.
Summary · context
A subset of patients from the parent study underwent 2 14-day periods of continuous glucose monitoring (CGM) at the start and end of the 24-week study.
Report a problemFND-2803246502
05HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes receiving pre-main-meal lixisenatide, HbA1c decreased by approximately 0.6% from baseline.
In plain wordsLong-term blood sugar decreased from baseline in patients receiving lixisenatide before their main meal.
Peptide
Lixisenatide
Outcome
DecreaseHbA1c change, before-main-meal group
Study
n = 29
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
HbA1c decrease
≈ 0.6%
main meal group
Source sentences
Summary
For patients included in the substudy, HbA_1c decreased by approximately 0.6% in both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Data were available for 69 patients in the substudy, 40 from the original breakfast group and 29 from the main meal group.
Summary · context
In the parent study of this analysis, patients with type 2 diabetes received lixisenatide before breakfast or the main meal of the day.
Summary · context
A subset of patients from the parent study underwent 2 14-day periods of continuous glucose monitoring (CGM) at the start and end of the 24-week study.
Report a problemFND-2803246504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring.

Summary

Results from this study5

Version history

Subjects

Publication types

MeSH terms

Keywords